4.5 Article

Bacterial blood stream infections (BSIs), particularly post-engraftment BSIs, are associated with increased mortality after allogeneic hematopoietic cell transplantation

Journal

BONE MARROW TRANSPLANTATION
Volume 54, Issue 8, Pages 1254-1265

Publisher

SPRINGERNATURE
DOI: 10.1038/s41409-018-0401-4

Keywords

-

Funding

  1. Public Health Service from the National Cancer Institute (NCI) [5U24CA076518]
  2. National Heart, Lung and Blood Institute (NHLBI)
  3. National Institute of Allergy and Infectious Diseases (NIAID)
  4. NHLBI [4U10HL069294]
  5. NCI [4U10HL069294]
  6. Health Resources and Services Administration (HRSA/DHHS) [HHSH250201200016C]
  7. Office of Naval Research [N00014-17-1-2388, N0014-17-1-2850]
  8. Actinium Pharmaceuticals, Inc.
  9. Amgen, Inc.
  10. Amneal Biosciences
  11. Angiocrine Bioscience, Inc.
  12. Astellas Pharma US
  13. Atara Biotherapeutics, Inc.
  14. Be the Match Foundation
  15. bluebird bio, Inc.
  16. Bristol Myers Squibb Oncology
  17. Celgene Corporation
  18. Cerus Corporation
  19. Chimerix, Inc.
  20. Fred Hutchinson Cancer Research Center
  21. Gamida Cell Ltd.
  22. Gilead Sciences, Inc.
  23. HistoGenetics, Inc.
  24. Immucor
  25. Incyte Corporation
  26. Janssen Scientific Affairs, LLC
  27. Jazz Pharmaceuticals, Inc.
  28. Juno Therapeutics
  29. Karyopharm Therapeutics, Inc.
  30. Kite Pharma, Inc.
  31. Medac, GmbH
  32. MedImmune
  33. Medical College of Wisconsin
  34. Mediware
  35. Merck Co, Inc.
  36. Mesoblast
  37. MesoScale Diagnostics, Inc.
  38. Millennium
  39. Takeda Oncology Co.
  40. Miltenyi Biotec, Inc.
  41. National Marrow Donor Program
  42. Neovii Biotech NA, Inc.
  43. Novartis Pharmaceuticals Corporation
  44. Otsuka Pharmaceutical Co, Ltd. - Japan
  45. PCORI
  46. Pfizer, Inc
  47. Pharmacyclics, LLC
  48. PIRCHE AG
  49. Sanofi Genzyme
  50. Seattle Genetics
  51. Shire
  52. Spectrum Pharmaceuticals Inc.
  53. St. Baldrick's Foundation
  54. Sunesis Pharmaceuticals, Inc.
  55. Swedish Orphan Biovitrum, Inc.
  56. Takeda Oncology
  57. Telomere Diagnostics, Inc.
  58. University of Minnesota

Ask authors/readers for more resources

We analyzed CIBMTR data to evaluate the incidence of non-relapse mortality (NRM) and association with overall survival (OS) for bacterial blood stream infections (BSIs) occurring within 100 days of alloHCT in 2 different phases: pre-/peri-engraftment (BSI very early phase, BSI-VEP) and BSI post-engraftment (BSI occurring between 2 weeks after engraftment and day 100, late early phase, BSI-LEP). Of the 7128 alloHCT patients, 2656 (37%) had >= 1 BSI by day 100. BSI-VEP, BSI-LEP, and BSI-Both constituted 56% (n=1492), 31% (n=824), and 13% (n=340) of total BSI, respectively. Starting in 2009, we observed a gradual decline in BSI incidence through 2012 (61-48%). Patients with BSI-VEP were more likely to receive a myeloablative conditioning (MAC) regimen with total body irradiation (TBI). NRM was significantly higher in patients with any BSI (RR 1.82 95% CI 1.63-2.04 for BSI-VEP, RR 2.46, 95% CI 2.05-2.96 for BSI-LEP, and RR 2.29, 95% CI 1.87-2.81 for BSI-Both) compared with those without BSI. OS was significantly lower in patients with any BSI compared with patients without BSI (RR 1.36, 95% CI 1.26-1.47 for BSI-VEP; RR 1.83, 95% CI 1.58-2.12 for BSI-LEP: RR 1.66, 95% CI 1.43-1.94 for BSI-Both). BSIs within day 100 after alloHCT are common and remain a risk factor for mortality.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available